Optimata Ltd.
Records under this name other than patents Optimata Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 10 of 10 · Back to Optimata Ltd.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,145,417 | Method and system for prediction of medical treatment effect Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,055,491 | System and methods for optimized drug delivery and progression of diseased and normal cells Formerly held Lapsed on the fee record Ended Nov 8, 2023 · From the USPTO record | Lapsed on the fee record | Ended Nov 8, 2023 | From the USPTO record |
| US 6,871,171 | System and methods for optimized drug delivery and progression of diseased and normal cells Term ended Term ended Oct 19, 2020 · From the USPTO record | Term ended | Term ended Oct 19, 2020 | From the USPTO record |
| US 7,266,483 | System and methods for optimized drug delivery and progression of diseased and normal cells Lapsed on the fee record Ended Sep 4, 2019 · From the USPTO record | Lapsed on the fee record | Ended Sep 4, 2019 | From the USPTO record |
| US 7,970,550 | Interactive technique for optimizing drug development from the pre-clinical phases through phase-IV Lapsed on the fee record Ended Jun 28, 2019 · From the USPTO record | Lapsed on the fee record | Ended Jun 28, 2019 | From the USPTO record |
| US 7,133,814 | System and Methods for Optimized Drug Delivery and Progression of Diseased and Normal Cells Lapsed on the fee record Ended Nov 7, 2018 · Medium confidence | Lapsed on the fee record | Ended Nov 7, 2018 | Medium confidence |
| US 8,650,017 | System and method of evaluation of stochastic interactions of a soluble ligand with a target cell population for optimization of drug design and delivery Lapsed on the fee record Ended Feb 11, 2018 · From the USPTO record | Lapsed on the fee record | Ended Feb 11, 2018 | From the USPTO record |
| US 8,504,303 | System and methods for optimized drug delivery and progression of diseased and normal cells Lapsed on the fee record Ended Aug 6, 2017 · From the USPTO record | Lapsed on the fee record | Ended Aug 6, 2017 | From the USPTO record |
| US 8,489,336 | Techniques for purposing a new compound and for re-purposing a drug Lapsed on the fee record Ended Jul 16, 2017 · From the USPTO record | Lapsed on the fee record | Ended Jul 16, 2017 | From the USPTO record |
| US 7,418,374 | Treatment protocol generation for diseases related to angiogenesis Lapsed on the fee record Ended Aug 26, 2016 · From the USPTO record | Lapsed on the fee record | Ended Aug 26, 2016 | From the USPTO record |